Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial

[1]  Michael R Kramer,et al.  Mortality Trends of Acute Respiratory Distress Syndrome in the United States from 1999 to 2013. , 2016, Annals of the American Thoracic Society.

[2]  Anders Larsson,et al.  Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. , 2016, JAMA.

[3]  F. Aeffner,et al.  Activation of A1-Adenosine Receptors Promotes Leukocyte Recruitment to the Lung and Attenuates Acute Lung Injury in Mice Infected with Influenza A/WSN/33 (H1N1) Virus , 2014, Journal of Virology.

[4]  S. Jalkanen,et al.  The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. , 2014, The Lancet. Respiratory medicine.

[5]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[6]  J. Kirk-Bayley,et al.  Functional Disability 5 Years after Acute Respiratory Distress Syndrome , 2011 .

[7]  A. Verin,et al.  Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement. , 2010, Vascular pharmacology.

[8]  World Medical Association (WMA),et al.  Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.

[9]  George Tomlinson,et al.  Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. , 2009, American journal of respiratory and critical care medicine.

[10]  S. Jalkanen,et al.  IFN‐β protects from vascular leakage via up‐regulation of CD73 , 2007, European journal of immunology.

[11]  Michel Mittelbronn,et al.  Identification of Ectonucleotidases CD39 and CD73 in Innate Protection during Acute Lung Injury1 , 2007, The Journal of Immunology.

[12]  Gordon R Bernard,et al.  Comparison of two fluid-management strategies in acute lung injury. , 2006, The New England journal of medicine.

[13]  Arthur S Slutsky,et al.  Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. , 2006, American journal of respiratory and critical care medicine.

[14]  G. Iapichino,et al.  Variable costs of ICU patients: a multicenter prospective study , 2006, Intensive Care Medicine.

[15]  S. Aberegg.  Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. , 2005, American journal of respiratory and critical care medicine.

[16]  S. Colgan,et al.  Crucial Role for Ecto-5′-Nucleotidase (CD73) in Vascular Leakage during Hypoxia , 2004, The Journal of experimental medicine.

[17]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[18]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[19]  D. Schoenfeld,et al.  Combining mortality and longitudinal measures in clinical trials. , 1999, Statistics in medicine.

[20]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[21]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[22]  J. L. Gall,et al.  APACHE II--a severity of disease classification system. , 1986, Critical care medicine.

[23]  R. Balk,et al.  Mortality Rates for Patients With Acute Lung Injury/ARDS Have Decreased Over Time , 2009 .